1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Bupropion for the Treatment of Methamphetamine Dependence (2007)

Bupropion for the Treatment of Methamphetamine Dependence (2007)

  1. Jatelka
    Neuropsychopharmacology. 2007 Jun 20

    Elkashef AM (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Rawson RA (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Anderson AL (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Li SH (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Holmes T (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Smith EV (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Chiang N (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Kahn R (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Vocci F (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Ling W (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Pearce VJ (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), McCann M (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Campbell J (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Gorodetzky C (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Haning W (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Carlton B (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Mawhinney J (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1), Weis D (http://www.ncbi.nlm.nih.gov/sites/e...bmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1).

    Bupropion was tested for efficacy in increasing weeks of abstinence in methamphetamine-dependent patients, compared to placebo. This was a double-blind placebo-controlled study, with 12 weeks of treatment and a 30-day follow-up. Five outpatient substance abuse treatment clinics located west of the Mississippi participated in the study. One hundred and fifty-one treatment-seekers with DSM-IV diagnosis of methamphetamine dependence were consented and enrolled. Seventy-two participants were randomized to placebo and 79 to sustained-release bupropion 150 mg twice daily. Patients were asked to come to the clinic three times per week for assessments, urine drug screens, and 90-min group psychotherapy. The primary outcome was the change in proportion of participants having a methamphetamine-free week. Secondary outcomes included: urine for quantitative methamphetamine, self-report of methamphetamine use, subgroup analyses of balancing factors and comorbid conditions, addiction severity, craving, risk behaviors for HIV, and use of other substances. The generalized estimating equation regression analysis showed that, overall, the difference between bupropion and placebo groups in the probability of a non-use week over the 12-week treatment period was not statistically significant (p=0.09). Mixed model regression was used to allow adjustment for baseline factors in addition to those measured (site, gender, level of baseline use, and level of symptoms of depression). This subgroup analysis showed that bupropion had a significant effect compared to placebo, among male patients who had a lower level of methamphetamine use at baseline (p

Recent Reviews

  1. HighTechHippie
    HighTechHippie
    5/5,
    Version: 2008-02-10
    Thanks for sharing!